How will Joint Clinical Assessment impact patient access to medicines in Europe?
Joint clinical assessment (JCA) has been implemented for new cancer medicines and advanced therapy medicinal products (ATMP) from January 2025 in the European Union (EU). The first panel session at the London 2025 Galien Foundation Forum focused on international health technology assessment (HTA) collaboration and the expected impact of JCA on patient access to medicines in the EU.
The panel included representatives from the European Patients’ Forum, the European Medicines Agency (EMA), the Member State Coordination Group on HTA (HTACG), the National Institute for Health and Care Excellence (NICE), and industry. They discussed the ambitions, challenges, and implications of a harmonized HTA process in Europe.
This advisory brief summarizes the key learnings from that panel.
Complete the form below to access the advisory brief.
By clicking "I agree" above, you are agreeing that Trinity will use and protect your personal data in accordance with our Privacy Policy. You can opt out of future marketing communications at any time by clicking the unsubscribe link at the bottom of any marketing email you receive from Trinity.